Research Institute of the ɬ�﷬ Health Centre (RI-MUHC)

COVID-19 boosters help avoid breakthrough infections in immunocompromised people, ɬ�﷬-led study finds

keila.depape@mcgill.ca — Wed, 26 Mar 2025 20:21:18 +0000

New research findings provide solid evidence that annual COVID-19 vaccine booster doses continue to be advisable for certain immunocompromised people, researchers at ɬ�﷬ say.

Experts: Halloween 2024

keila.depape@mcgill.ca — Thu, 24 Oct 2024 20:56:07 +0000

With Halloween approaching, ɬ�﷬ experts are available to offer insights on a range of related topics.

Using AI to predict recurring lung cancer

claire.loewen@mcgill.ca — Thu, 02 Feb 2023 15:04:56 +0000

Lung cancer is the leading cause of cancer-related deaths in Quebec and Canada, killing more individuals than prostate, colon and breast cancers combined. Thanks to tissue samples from almost 500 lung cancer patients, a group of researchers from ɬ�﷬ and Université Laval were able to identify those who were likely to have a cancer recurrence and require further treatment post-surgery.

ɬ�﷬ and RI-MUHC awarded $5.1 million for infectious disease research

katherine.gombay@mcgill.ca — Wed, 16 Nov 2022 12:56:10 +0000

New funding of $5.1 million from the Canada Foundation for Innovation (CFI), announced today by the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, will help researchers Marcel Behr, MD, PhD, and Silvia Vidal, PhD, ensure that Canada is better prepared for the next pandemic. This funding is part of the more than $127 million investment being made through the CFI to support upgrades to eight biocontainment facilities across the country as part of its new Biosciences Research Infrastructure Fund (BRIF) program.

Can inhaled corticosteroids alleviate early symptoms of COVID-19?

katherine.gombay@mcgill.ca — Tue, 02 Nov 2021 13:37:42 +0000

Despite high hopes, a new pan-Canadian study published today in The BMJ suggests that ciclesonide—an inhaled and nasal steroid drug commonly used for asthma and rhinitis—won’t be the treatment to change the course of the pandemic.